Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 20, 2018-- Incyte (Nasdaq:INCY) today announced that the first patient has been...
Health News 2 me
healthnews2me.com
Category: Medications
Surgeon General: Federal drug classification needs changes
The nation's drug classification system should be revisited but illegal drugs shouldn't simply be decriminalized...
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
CAMBRIDGE, Mass., Dec. 2, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in...
Pain common and increasing in prevalence in New Zealand
Pain is an extremely common condition and increasing in prevalence in New Zealand, University of...
An opioid epidemic may be looming in Mexico—and the US may be partly responsible
Though opioid use in Mexico has been low, national and international factors are converging and...
FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease
ROCKVILLE, Md., Nov. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology...
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
Will My Insurance Pay For GoodRx? It's Worth A Try – Here's Why.
Nearly half of Americans now have high-deductible health plans (HDHPs), which means they’re...
Study examines opioid use among Massachusetts adolescents, trends in opioid prescriptions
Opioid-related overdoses and deaths remain a major public health concern in Massachusetts, yet adolescents who...
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
WHIPPANY, N.J., Oct. 24, 2018 /PRNewswire/ -- The Phase III ARAMIS (Androgen Receptor inhibiting Agent...